Lantheus (LNTH) said Wednesday its radiodiagnostic MK-6240 to treat Alzheimer's disease met its co-primary endpoints in two trials evaluating its sensitivity and specificity.
The results from the two trials will back a new drug application with the US Food and Drug Administration, which is expected to be filed in Q3, the company said.
MK-6240 was designed to complement Lantheus' imaging agent NAV-4694, which is in phase 3 development and is used in academic and industry-led investigational trials for Alzheimer's disease, the company said.
The company's shares were down 0.5% in recent trading.
Price: 103.00, Change: -0.96, Percent Change: -0.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.